Effect of 3-aminobenzamide, PARP inhibitor, on matrix metalloproteinase-9 level in plasma and brain of ischemic stroke model.

摘要: We investigated the effect of poly(ADP-ribose) polymerase (PARP) inhibitor on levels plasma and brain matrix metalloproteinase-9 (MMP-9) expression nuclear factor kappa B (NF-kappaB) during experimental focal cerebral ischemia. The 3-aminobenzamide (3-AB), a PARP inhibitor, saline were administered to 80 Sprague-Dawley rats [3-AB group; 5 for sampling, 35 40 TTC staining] 85 (10, 35, 40, respectively), respectively, 10 min before occlusion left middle artery (MCAo) 2 h. Infarct volume was measured by staining, serial MMP-9 zymography just 2, 4, 8, 24, 48, 72 h after MCAo, NF-kappaB activity determined Western blotting, neutrophil infiltration evaluated assessing myeloperoxidase activity. Compared with control group, MMP-9, NF-kappaB, MPO activities significantly reduced in 3-AB group at each time point (p<0.05). Plasma increased maximally 4h then decreased rapidly, 24 persisted until h, 24h slowly both groups. Therefore, reduces neutrophils ischemic stroke.